Search

Cytoreductive surgery for advanced ovarian cancer is safe in older women, even those who present with frailty.

… Thursday, September 19, 2019 Cytoreductive surgery for advanced ovarian cancer is safe in older women, even those who present with frailty, according to our recent prospective study of 42 patients treated at Memorial Sloan Kettering Cancer Center. Despite a high rate of preoperative impairments, there

Memorial Sloan Kettering Cancer Center (MSK) is now recognized as the first dedicated cancer center in the United States to be designated as a qualified provider-led entity (QPLE) under Medicare’s program for appropriate use criteria (AUC). This designation allows MSK to establish best practice standards for the use of CT scans, MRI, and nuclear medicine imaging from initial screening and diagnosis through all stages of cancer care, including survivorship.

… Tuesday, September 19, 2017 New York, NY - Memorial Sloan Kettering Cancer Center (MSK) has become the first dedicated cancer center in the U.S. to be designated a qualified provider-led entity (QPLE) under the Medicare Appropriate Use Criteria (AUC) program. This designation allows MSK to establish

Joan Massagué, Chair of the Cancer Biology and Genetics Program in the Sloan Kettering Institute, has been named the recipient of two prestigious awards.

… Friday, May 1, 2009 Summary Joan Massagué, Chair of the Cancer Biology and Genetics Program in the Sloan Kettering Institute, has been named the recipient of two prestigious awards. Joan Massagué , Chair of the Cancer Biology and Genetics Program in the Sloan Kettering Institute , has been named the

Research led by Josie Robertson Investigator Karuna Ganesh provided clues that microbiomes might explain the increase in colorectal cancer among younger patients.

… Wednesday, April 19, 2023 At a worldwide gathering of the American Association for Cancer Research (AACR), Memorial Sloan Kettering Cancer Center (MSK) scientists presented new insights into the connection between cancer and the gut microbiome, often referred to as the “forgotten organ.” Their findings

Memorial Sloan Kettering Cancer Center has announced that Oren Cahlon, MD, a renowned radiation oncologist and expert in proton therapy, will assume the position of Associate Deputy Physician-in-Chief for the Memorial Sloan Kettering Regional Care Network. With this appointment, which is effective immediately, Dr. Cahlon will help oversee the network’s outpatient clinical programs, which span seven locations across New York and New Jersey.

… Friday, November 23, 2018 Memorial Sloan Kettering Cancer Center has announced that Oren Cahlon, MD , a renowned radiation oncologist and expert in proton therapy, will assume the position of Associate Deputy Physician-in-Chief for the Memorial Sloan Kettering Regional Care Network. With this appointment

Memorial Sloan Kettering Cancer Center (MSK) announced today that the US Food and Drug Administration (FDA) has granted a Breakthrough Therapy Designation to cobimetinib in treatment of patients with histiocytic neoplasms (HN) (Erdheim-Chester Disease, Rosai-Dorfman, Langerhans Histiocytosis), who do not harbor the BRAF V600 mutation. Cobimetinib is an oral inhibitor of MEK1 and MEK2 currently approved to treat melanoma. This designation was granted based on data submitted by MSK, in collaboration with Genentech, a member of the Roche Group, from a phase II trial of single-agent cobimetinib for adults with histiocytic disorders (published in Nature in March 2019 by Eli Diamond, MD; Omar Abdel-Wahab, MD; and David Hyman, MD).

… Wednesday, October 2, 2019 Bottom Line: Memorial Sloan Kettering Cancer Center (MSK) announced today that the US Food and Drug Administration (FDA) has granted a Breakthrough Therapy Designation to cobimetinib in treatment of patients with histiocytic neoplasms (HN) (Erdheim-Chester Disease, Rosai-Dorfman

MSK President and CEO, Craig B. Thompson, MD, has been named a founding member of the New York Jobs CEO Council. Dr. Thompson joins CEOs from 27 of the largest employers in New York in the new CEO-led, action-oriented coalition.

… Tuesday, August 11, 2020 Memorial Sloan Kettering President and CEO, Craig B. Thompson, MD , has been named a founding member of the New York Jobs CEO Council. Dr. Thompson joins CEOs from 27 of the largest employers in New York in the new CEO-led, action-oriented coalition. The council will collaborate

Scientists are dusting off their biochemistry textbooks in the hunt for clues to cancer.

… Wednesday, November 23, 2016 Summary Prompted by MSK President and CEO Craig Thompson , cancer researchers are returning to the topic of metabolism for answers about what makes cancer cells go haywire. Highlights Metabolism refers to how cells acquire nutrients and energy. The products of metabolism

Cell biologist Michael Overholtzer will succeed DNA replication expert Ken Marians.

… Friday, October 19, 2018 Call it a changing of the guard. Come January 1, 2019, the Gerstner Sloan Kettering Graduate School of Biomedical Sciences (GSK) — MSK’s PhD-granting institution — will have a new dean. GSK’s Board of Trustees voted yesterday to appoint cell biologist Michael Overholtzer to this

Seven students have successfully defended their dissertations and will receive their PhD degrees at commencement on May 18.

… Tuesday, May 16, 2017 Summary Seven students will receive their doctorate degrees this week from the Louis V. Gerstner, Jr. Graduate School of Biomedical Sciences at Memorial Sloan Kettering. This innovative program prepares the next generation of basic laboratory scientists to work in research areas